Am J Physiol Cell Physiol AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Cell Physiol (August 30, 2006). doi:10.1152/ajpcell.00406.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/3/C987    most recent
00406.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.
Submitted on July 26, 2006
Accepted on August 23, 2006

Stromal derived factor (SDF-1/CXCL12) and human tumor pathogenesis

Ilona Kryczek1, Shuang Wei1, Evan Keller2, Rebecca Liu3, and Weiping Zou4*

1 Surgery, University of Michigan, Ann Arbor, Michigan, United States
2 Urology, University of Michigan, Ann Arbor, Michigan, United States
3 Obstetrics and Gyn, University of Michigan, Ann Arbor, Michigan, United States
4 University of Michigan School of Medicine, 1150 W. Medical Center Dr., Ann Arbor, Michigan, 48109-0669, United States

* To whom correspondence should be addressed. E-mail: wzou{at}umich.edu.

The chemokine stroma-derived-factor (SDF-1/CXCL12) plays multiple roles in tumor pathogenesis. It has been demonstrated that CXCL12 promotes tumor growth and malignancy, enhances tumor angiogenesis, participates in tumor metastasis, and contributes to immunosuppressive networks within the tumor microenvironment. Therefore, it stands to reason that the CXCL12/CXCR4 pathway is an important target for the development of novel anti-cancer therapies. In this review, we will consider the pathological nature and characteristics of the CXCL12/CXCR4 pathway in the tumor microenvironment. Strategies for therapeutically targeting the CXCL12/CXCR4 axis are also discussed.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
Correlation of CXCL12 Expression and FoxP3+ Cell Infiltration with Human Papillomavirus Infection and Clinicopathological Progression of Cervical Cancer
Am. J. Pathol., October 1, 2009; 175(4): 1525 - 1535.


Home page
 Clin. Cancer Res.Home page
L. Fischer, A. Korfel, S. Pfeiffer, P. Kiewe, H.-D. Volk, H. Cakiroglu, T. Widmann, and E. Thiel
CXCL13 and CXCL12 in Central Nervous System Lymphoma Patients
Clin. Cancer Res., October 1, 2009; 15(19): 5968 - 5973.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Kwong, H. Kulbe, D. Wong, P. Chakravarty, and F. Balkwill
An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells
Mol. Cancer Ther., July 1, 2009; 8(7): 1893 - 1905.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.